BACKGROUND: Asthma was the most common comorbidity of patients hospitalized with 2009 H1N1 influenza. OBJECTIVE: We sought to assess the immunogenicity and safety of an unadjuvanted, inactivated 2009 H1N1 vaccine in patients with severe versus mild-to-moderate asthma. METHODS: We conducted an open-label study involving 390 participants (age, 12-79 years) enrolled in October-November 2009. Severe asthma was defined as need for 880 μg/d or more of inhaled fluticasone equivalent, systemic corticosteroids, or both. Within each severity group, participants were randomized to receive intramuscularly 15 or 30 μg of 2009 H1N1 vaccine twice 21 days apart. Immunogenicity end points were seroprotection (hemagglutination inhibition assay titer ≥40) and seroconversion (4-fold or greater titer increase). Safety was assessed through local and systemic reactogenicity, asthma exacerbations, and pulmonary function. RESULTS: In patients with mild-to-moderate asthma (n = 217), the 2009 H1N1 vaccine provided equal seroprotection 21 days after the first immunization at the 15-μg (90.6%; 95% CI, 83.5% to 95.4%) and 30-μg (95.3%; 95% CI, 89.4% to 98.5%) doses. In patients with severe asthma (n = 173), seroprotection 21 days after the first immunization was 77.9% (95% CI, 67.7% to 86.1%) and 94.1% (95% CI, 86.8% to 98.1%) at the 15- and 30-μg doses, respectively (P = .004). The second vaccination did not provide further increases in seroprotection. Participants with severe asthma who are older than 60 years showed the lowest seroprotection (44.4% at day 21) with the 15-μg dose but had adequate seroprotection with 30 μg. The 2 dose groups did not differ in seroconversion rates. There were no safety concerns. CONCLUSION:Monovalent inactivated 2009 H1N1 pandemic influenza vaccine was safe and provided overall seroprotection as a surrogate of efficacy. In patients older than 60 years with severe asthma, a 30-μg dose might be more appropriate. Published by Mosby, Inc.
RCT Entities:
BACKGROUND:Asthma was the most common comorbidity of patients hospitalized with 2009 H1N1influenza. OBJECTIVE: We sought to assess the immunogenicity and safety of an unadjuvanted, inactivated 2009 H1N1 vaccine in patients with severe versus mild-to-moderate asthma. METHODS: We conducted an open-label study involving 390 participants (age, 12-79 years) enrolled in October-November 2009. Severe asthma was defined as need for 880 μg/d or more of inhaled fluticasone equivalent, systemic corticosteroids, or both. Within each severity group, participants were randomized to receive intramuscularly 15 or 30 μg of 2009 H1N1 vaccine twice 21 days apart. Immunogenicity end points were seroprotection (hemagglutination inhibition assay titer ≥40) and seroconversion (4-fold or greater titer increase). Safety was assessed through local and systemic reactogenicity, asthma exacerbations, and pulmonary function. RESULTS: In patients with mild-to-moderate asthma (n = 217), the 2009 H1N1 vaccine provided equal seroprotection 21 days after the first immunization at the 15-μg (90.6%; 95% CI, 83.5% to 95.4%) and 30-μg (95.3%; 95% CI, 89.4% to 98.5%) doses. In patients with severe asthma (n = 173), seroprotection 21 days after the first immunization was 77.9% (95% CI, 67.7% to 86.1%) and 94.1% (95% CI, 86.8% to 98.1%) at the 15- and 30-μg doses, respectively (P = .004). The second vaccination did not provide further increases in seroprotection. Participants with severe asthma who are older than 60 years showed the lowest seroprotection (44.4% at day 21) with the 15-μg dose but had adequate seroprotection with 30 μg. The 2 dose groups did not differ in seroconversion rates. There were no safety concerns. CONCLUSION: Monovalent inactivated 2009 H1N1 pandemic influenza vaccine was safe and provided overall seroprotection as a surrogate of efficacy. In patients older than 60 years with severe asthma, a 30-μg dose might be more appropriate. Published by Mosby, Inc.
Authors: Douglas M Fleming; Pietro Crovari; Ulrich Wahn; Timo Klemola; Yechiel Schlesinger; Alexangros Langussis; Knut Øymar; Maria Luz Garcia; Alain Krygier; Herculano Costa; Ulrich Heininger; Jean-Louis Pregaldien; Sheau-Mei Cheng; Jonathan Skinner; Ahmad Razmpour; Melanie Saville; William C Gruber; Bruce Forrest Journal: Pediatr Infect Dis J Date: 2006-10 Impact factor: 2.129
Authors: Anthony E Fiore; David K Shay; Karen Broder; John K Iskander; Timothy M Uyeki; Gina Mootrey; Joseph S Bresee; Nancy S Cox Journal: MMWR Recomm Rep Date: 2008-08-08
Authors: Seema Jain; Laurie Kamimoto; Anna M Bramley; Ann M Schmitz; Stephen R Benoit; Janice Louie; David E Sugerman; Jean K Druckenmiller; Kathleen A Ritger; Rashmi Chugh; Supriya Jasuja; Meredith Deutscher; Sanny Chen; John D Walker; Jeffrey S Duchin; Susan Lett; Susan Soliva; Eden V Wells; David Swerdlow; Timothy M Uyeki; Anthony E Fiore; Sonja J Olsen; Alicia M Fry; Carolyn B Bridges; Lyn Finelli Journal: N Engl J Med Date: 2009-10-08 Impact factor: 91.245
Authors: Tristan W Clark; Manish Pareek; Katja Hoschler; Helen Dillon; Karl G Nicholson; Nicola Groth; Iain Stephenson Journal: N Engl J Med Date: 2009-09-10 Impact factor: 91.245
Authors: Nizar N Jarjour; Serpil C Erzurum; Eugene R Bleecker; William J Calhoun; Mario Castro; Suzy A A Comhair; Kian Fan Chung; Douglas Curran-Everett; Raed A Dweik; Sean B Fain; Anne M Fitzpatrick; Benjamin M Gaston; Elliot Israel; Annette Hastie; Eric A Hoffman; Fernando Holguin; Bruce D Levy; Deborah A Meyers; Wendy C Moore; Stephen P Peters; Ronald L Sorkness; W Gerald Teague; Sally E Wenzel; William W Busse Journal: Am J Respir Crit Care Med Date: 2011-11-17 Impact factor: 21.405
Authors: Karthik D Nath; Julie G Burel; Viswanathan Shankar; Antonia L Pritchard; Michelle Towers; David Looke; Janet M Davies; John W Upham Journal: Int J Chron Obstruct Pulmon Dis Date: 2013-12-24